Cargando…
Toxicity evaluation of ConvitVax breast cancer immunotherapy
ConvitVax is a personalized vaccine for the treatment of breast cancer, composed of autologous tumor cells, bacillus Calmette-Guérin (BCG) and low concentrations of formalin. Previous pre-clinical studies show that this therapy induces a potent activation of the immune system and achieves an effecti...
Autores principales: | Duarte C., María A., Carballo O., Jeismar M., De Gouveia, Yetsenia M., García, Angie, Ruiz, Diana, Gledhill, Teresa, González-Marcano, Eglys, Convit, Ana F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209199/ https://www.ncbi.nlm.nih.gov/pubmed/34135375 http://dx.doi.org/10.1038/s41598-021-91995-6 |
Ejemplares similares
-
Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment
por: Godoy-Calderón, María José, et al.
Publicado: (2019) -
Dr. Jacinto Convit (1913–2014)
por: Paniz Mondolfi, Alberto E., et al.
Publicado: (2014) -
Autologous tumor cells/bacillus Calmette-Guérin/formalin-based novel breast cancer vaccine induces an immune antitumor response
por: Godoy-Calderón, María José, et al.
Publicado: (2018) -
Electrocardiogram classification using TSST-based spectrogram and ConViT
por: Bing, Pingping, et al.
Publicado: (2022) -
To vax or not to vax: Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine availability
por: Roberts, Hannah A., et al.
Publicado: (2022)